Anglonordic Life Science Conference
Optimum Strategic Communications are supporters of the Anglonordic Life Science Conference that will take place on Thursday 24th May at the County Hall, Central London, SE1 7PB (near Parliament Square and Waterloo Station).
Anglonordic is the only life science conference in the UK that is exclusively for European investors and R&D companies from the Nordics and the UK to connect with each other. With an established format of panel discussions, parallel technology and biotech investment rooms, and 1:1 meetings, the conference provides exceptional value.
If you are interested in attending, please register using the following link: www.weezevent.com/anglonordic-life-science-conference
Complimentary passes are available for media and investors.
9:00 am Welcome From the Conference Founder: Mattias Johansson, Director, Ezenze Ltd
9:05 Keynote from Dr Søren Bregenholt, Corporate VP, Global Research Strategy and Operations, Novo Nordisk
9:30 What’s on the hotplate and what’s simmering at the surface
(Panel discussion on Investment trends)
Hakan Goker, MVentures; Deborah Harland, SR One; Jonas Brambeck, Industrifonden; Henrijette Richter, Sofinnova.
10:15 Reproductive Medicine & Women’s Health: A key area for Ferring Pharmaceuticals
Dr Henk Jan Out, VP Reproductive Medicine & Women’s Health, Global Clinical R&D,
11:00 Company presentations
13:30 Technologies and Treatments for Women’s Health (Panel Discussion) Chaired by Lucie Ellis, Scrip Pink Sheet and In Vivo
Henk Jan Out, Ferring; Stephan Christgau, Novo Seeds; Risto Lammintausta, Forendo Pharma; Fiona MacLaughlin, INKEF Capital; Ksenija Pavletic, PregLem SA, Vincent Attallah, Merck; Kristof Chwalisz, Abbvie.
14:15 Company presentations
15:45 Challenges and opportunities of managing a European biotech company (Panel Session) Chaired by Darren Dodd, FT Health, Financial Times.
John Haurum, F-star Biotechnology; Frans Wuite, Acesion Pharma; Catherine Pickering, ionctura
16:30 If I knew then what I know today (Panel Discussion) Chaired by Mike Ward, Scrip
Anker Lundemose, Mission Therapeutics; David Colpman, Forendo Pharma,HRA Pharma,Orexo AB; Annalisa Jenkins, PlaqueTec; Allan Marchington, Apposite Capital; Jeanne Bolger, J&J Venture Investments
Hakan Goker, M Ventures and Mary Clark, Optimum Strategic Communications